Schrodinger, Inc. (SDGR)
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
- Symbol
- SDGR
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Health Information Services
- Market cap
- $2.29B
- 52 week range
- 10.94 - 31.14
Valuation
- Share price
- $29.23 (close of 2026-09-23)
- P/E (TTM)
- -42.05x
- Price to book
- 6.97x
- Price to free cash flow
- -17.61x
- Enterprise value
- $2.11B
- Book value per share
- $4.40
Price performance
| Period | Change |
|---|
| 1 day | -3.34% |
| 5 days | +25.72% |
| 1 month | +48.30% |
| 3 months | +94.35% |
| 6 months | +146.25% |
| Year to date | +63.48% |
| 1 year | +53.36% |
| 3 years | +0.69% |
| 5 years | -51.69% |
| All time | +2.06% |
Profitability and growth
- Return on equity
- -28.37%
- Return on invested capital
- -68.75%
- Return on assets
- -14.22%
- Return on capital employed
- -31.08%
- Gross margin
- 55.74%
- Net margin
- -40.36%
- EBITDA margin
- -62.87%
- Revenue growth
- 23.29%
- Net income growth
- 44.81%
- Free cash flow growth
- 107.56%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -5.68%
- Current ratio
- 2.71x
- Net debt to EBITDA
- 1.22x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $255.87M
- Cost of revenue
- $113.25M
- Gross profit
- $142.61M
- EBITDA
- $-160.87M
- Net income
- $-103.27M
- Earnings per share
- $-1.41
- Research and development
- $173.14M
- Shares outstanding
- 73.44M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $255.87M | $142.61M | $-103.27M | $-1.41 |
| 2024-12-31 | $207.54M | $132.08M | $-187.12M | $-2.57 |
| 2023-12-31 | $216.67M | $140.69M | $40.72M | $0.57 |
| 2022-12-31 | $180.96M | $101.02M | $-149.19M | $-2.10 |
| 2021-12-31 | $137.93M | $65.62M | $-100.39M | $-1.42 |
| 2020-12-31 | $108.09M | $63.47M | $-24.46M | $-0.41 |
| 2019-12-31 | $85.54M | $49.09M | $-24.57M | $-4.09 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 55.74% | -40.36% | -28.37% | -68.75% |
| 2024-12-31 | 63.64% | -90.16% | -44.40% | -53.40% |
| 2023-12-31 | 64.93% | 18.79% | 7.42% | -34.05% |
| 2022-12-31 | 55.83% | -82.44% | -33.31% | -30.98% |
| 2021-12-31 | 47.57% | -72.78% | -18.02% | -21.57% |
| 2020-12-31 | 58.72% | -22.63% | -3.92% | -14.05% |
| 2019-12-31 | 57.39% | -28.72% | 26.33% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $230.52M |
| 2024-12-31 | $147.33M |
| 2023-12-31 | $155.31M |
| 2022-12-31 | $90.47M |
| 2021-12-31 | $120.27M |
| 2020-12-31 | $202.30M |
| 2019-12-31 | $25.99M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $12.46M | $43.00M |
| 2024-12-31 | $-164.68M | $49.90M |
| 2023-12-31 | $-150.14M | $47.84M |
| 2022-12-31 | $-127.70M | $39.63M |
| 2021-12-31 | $-77.84M | $26.49M |
| 2020-12-31 | $14.22M | $10.54M |
| 2019-12-31 | $-27.89M | $2.19M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | - |
| 2026-05-05 | - | - |
| 2026-02-25 | - | - |
| 2025-11-05 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-02-26 | - | - |
| 2024-11-12 | - | - |
Filings and sources
- Company website
- schrodinger.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades